<code id='CBC3A3EAC8'></code><style id='CBC3A3EAC8'></style>
    • <acronym id='CBC3A3EAC8'></acronym>
      <center id='CBC3A3EAC8'><center id='CBC3A3EAC8'><tfoot id='CBC3A3EAC8'></tfoot></center><abbr id='CBC3A3EAC8'><dir id='CBC3A3EAC8'><tfoot id='CBC3A3EAC8'></tfoot><noframes id='CBC3A3EAC8'>

    • <optgroup id='CBC3A3EAC8'><strike id='CBC3A3EAC8'><sup id='CBC3A3EAC8'></sup></strike><code id='CBC3A3EAC8'></code></optgroup>
        1. <b id='CBC3A3EAC8'><label id='CBC3A3EAC8'><select id='CBC3A3EAC8'><dt id='CBC3A3EAC8'><span id='CBC3A3EAC8'></span></dt></select></label></b><u id='CBC3A3EAC8'></u>
          <i id='CBC3A3EAC8'><strike id='CBC3A3EAC8'><tt id='CBC3A3EAC8'><pre id='CBC3A3EAC8'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:Wikipedia    Page View:1996
          Exterior photo of UnitedHealth Group building
          UnitedHealth Group is attempting to buy Amedisys for $3.3 billion. Courtesy UnitedHealth Group

          There’s now a two-party showdown for one of the largest home health companies in the country.

          UnitedHealth Group and its Optum division on Monday formally proposed to buy Amedisys for $100 per share, or about $3.3 billion.

          advertisement

          The offer comes a few weeks after Option Care Health proposed a $3.6 billion takeover. However, Option Care’s deal is an all-stock transaction, whereas UnitedHealth would pay all cash — a potentially more attractive offer for Amedisys shareholders who want a more immediate payout that isn’t tied to the unpredictability of another company’s stock price. Option Care’s offer is technically worth closer to $2.8 billion now, due to the drop in Option Care’s stock price since the merger was announced. Amedisys is recommending shareholders vote in favor of the deal with Option Care.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          comprehensive

          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more
          An innovative path out of biotech’s “valley of death”
          An innovative path out of biotech’s “valley of death”

          AdobeSomanypromisingmedicalinnovationsneverreachtheirfullpotentialastherapiesorcures,languishinginst

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          An innovative path out of biotech’s “valley of death”

          AdobeSomanypromisingmedicalinnovationsneverreachtheirfullpotentialastherapiesorcures,languishinginst